Hearing loss in patients using isotretinoin: is it a side effect or due to hyperlipidemia?

Abstract

Objective: To prospectively investigate the effect of isotretinoin therapy on the functions of hearing and to show the relationship between concurrent triglyceride levels. Methods: A total of 47 patients who were admitted to our dermatology clinic between February 2011 and June 2011 for the treatment of acne using 0.5 mg/kg isotretinoin were included in this study. All the patients were started on 0.5 mg/kg/day isotretinoin depending on their tolerance of the drug. Details such as age, sex, dose of isotretinoin for the first 6 months, monthly pretreatment and posttreatment, and ALT, AST, triglyceride and total cholesterol values were recorded. There were 33 females and 14 males in the study group. Results: Audiometric evaluations made prior to treatment with isotretinoin, levels of PTA1 and PTA2 were 11.96 and 12.59, respectively, these were compared with the results of tests carried out after the treatment and pre- and posttreatment values of PTA1 and PTA2 were found to be the same, 1 month after the treatment, drug use did not effect hearing. PTA 1 value after 3 months was 12.16 and PTA 2 value was 13.85. These values are compared to pretreatment values and PTA2 PTA1 both were decreased. However, in the third month the threshold decrease was not statistically significant (p>0.05). PTA1 and PTA2 values after the sixth month were 12.25 and 12.96, this decrease was statistically significant compared with pretreatment values (p

Keywords

• Acne vulgaris, drug therapy, side effects, hearing loss, hyperlipidemia

İzoretinoin kullanan hastalarda işitme kaybı: Bir yan etki mi yoksa nedeni hiperlipidemi mi?

Öz

Amaç: Bu çalışmanın amacı, izoretinoin tedavisinin işitme fonksiyonları üzerine etkisini prospektif olarak araştırmak ve eş zamanlı trigliserit düzeyleriyle ilişkisini göstermektir. Yöntem: Bu çalışmaya aknelerinin 0.5 mg/kg izoretinoinle tedavisi için Şubat 2011 - Haziran 2011 tarihleri arasında dermatoloji kliniğimize kabul edilen toplam 47 hasta dahil edilmiştir. İlacı tolere edebilme derecelerine göre hastaların hepsinde günlük 0.5 mg/kg izoretinoin dozuyla tedaviye başlanmıştır. Yaş, cinsiyet, ilk 6 ayda izoretinoin dozu, tedavi öncesi ve sonrası aylık AST, ALT, trigliserit ve total kolesterol değerleri kaydedilmiştir. Çalışma grubunda 33 kadın ve 14 erkek katılımcı vardı. Bulgular: İzoretinoinle tedaviye başlamadan önce odyometrik değerlendirmeler yapılmıştır. PTA1 ve PTA2 değerleri sırasıyla 11.96 ve 12.59 idi. Bu değerler tedavi sonrası testlerin sonuçları ile karşılaştırılmış, tedavi sonrası PTA1 ve PTA2 sonuçlarının aynı olduğu saptanmıştır. İlacın kullanımı tedaviden 1 ay sonra işitmeyi etkilememişti. Üç ay sonra PTA1 ve PTA2 değerleri sırasıyla 12.16 ve 13.85 idi. Bu değerler tedavi öncesi değerlerle karşılaştırılmış, hem PTA1, hem de PTA2 düzeylerinin azaldığı saptanmıştır. Ancak 3. ayda eşik değerdeki azalma istatistiksel açıdan anlamlı değildi (p

Anahtar Kelimeler

• Akne vulgaris, ilaç tedavisi, yan etkiler, işitme kaybı, hiperlipidemi

References

1. Layton A. The use of isotretinoin in acne. Dermatoendocrinol 2009;1:162-9.
2. Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI. Fitzpatrick’s dermatology in general medicine. 6th ed. New York: McGraw-Hill; 2003.
3. Orfanos CE, Zouboulis CC, Almond-Roesler B, Geilen CC. Current use and future potential role of retinoids in dermatology. Drugs 1997;53:358-88.
4. Kanigsberg N, DesGroseilliers JP. Use of 13-cis-retinoic acid in cystic acne. Can Med Assoc J 1983;129:224,228.
5. Altman RS, Altman LJ, Altman JS. A proposed set of new guide- lines for routine blood tests during isotretinoin therapy for acne vulgaris. Dermatology 2002;204:232-5.
6. Mahasitthiwat V. A woman with sudden bilateral sensorineural hearing loss after treatment psoriasis with Acitretin. J Med Assoc Thai 2005;88 Suppl 1:S79-81.
7. Tallab T, Joharji H, Jazei M, Bahamdan K, Ibrahim K, Karkashan E. Isotretinoin therapy: any need for laboratory assessment? West Afr J Med 2004;23:273-5.
8. Bigby M, Stern RS. Adverse reactions to isotretinoin. A report from the Adverse Drug Reaction Reporting System. J Am Acad Dermatol 1988;18:543-52.

9. Karlida¤ T, Açik Y, Kaygusuz I, Yalçin S, Güngör MY, Demirba¤ E. The effect of hyperlipidemia on hearing function. Kulak Burun Bogaz Ihtis Derg 2002;9:112-6.
10. Thakur JS, Mohindroo NK, Vasanthalakshmi MS, Kashyap N, Azad RK, Sharma DR. Auditory brainstem evoked responses in hyperlipidaemia: effect of various lipid fractions on auditory func- tion. J Laryngol Otol 2012;126:249-56.
11. Rosende L, Verea-Hernando MM, de Andrés A, et al. Hypoacusia in a patient treated by isotretinoin. Case Report Med 2011; 2011:789143.
12. Boer J, Nazary M. Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer? Br J Dermatol 2011;164:170-5.
13. Aydogan K, Turan OF, Onart S, Yazici B, Karadogan SK, Tokgoz N. Neurological and neurophysiological effects of oral isotretinoin: a prospective investigation using auditory and visu- al evoked potentials. Eur J Dermatol 2008;18:642-6.
14. Nikiforidis G, Tsambaos D, Karamitsos D, Koutsojannis C, Georgiou S. Effects of oral isotretinoin on human auditory brain- stem response. Dermatology 1994;189:62-4.
15. Karabulut H, Karadag AS, Acar B, et al. The effect of oral isotretinoin (13-cis retinoic acid) on hearing systems in patients with acne vulgaris: a prospective study. Int J Dermatol 2011;50: 1139-41.
16. Kojima Y, Ito S, Furuya N. Hearing improvement after therapy for hyperlipidemia in patients with chronic-phase sudden deaf- ness. Ann Otol Rhinol Laryngol 2001;110:105-8.
17. Sutbas A, Yetiser S, Satar B, Akcam T, Karahatay S, Saglam K. Low-cholesterol diet and antilipid therapy in managing tinnitus and hearing loss in patients with noise-induced hearing loss and hyperlipidemia. Int Tinnitus J 2007;13:143-9.
18. Satar B, Ozkaptan Y, Sürücü HS, Oztürk H. Ultrastructural effects of hypercholesterolemia on the cochlea. Otol Neurotol 2001;22: 786-9.
19. Jones NS, Davis A. A prospective case-control study of 50 consec- utive patients presenting with hyperlipidaemia. Clin Otolaryngol Allied Sci 2001;26:189-96.
20. Jones NS, Davis A. A prospective case-controlled study of patients presenting with idiopathic sensorineural hearingloss to examine the relationship between hyperlipidaemia and sensorineural hear- ing loss. Clin Otolaryngol Allied Sci 1999;24:531-6.
21. Jones NS, Davis A. A retrospective case-controlled study of 1490 consecutive patients presenting to a neuro-otology clinic to exam- ine the relationship between blood lipid levels and sensorineural hearing loss. Clin Otolaryngol Allied Sci 2000;25:511-7.
22. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported (CC BY
23. NC-ND0) Licence (http://creativecommons.org/licenses/by-nc-nd/3.0/) which permits unrestricted noncommercial use, distribution, and reproduc
24. tion in any medium, provided the original work is properly cited.
25. Please cite this article as: Boztepe OF, Alan S, Gün T, Özcan KM, Gür ÖE. Hearing loss in patients using isotretinoin: is it a side effect or due to hyper
26. lipidemia? J Med Updates 2013;3(2):82-86.